Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors.

导出原文传递

翻译打印收藏纠错

作者： Ryugo,Teranishi ^[1] ; Tsuyoshi,Takahashi ^[1] ; Yuuki,Obata ^[2] ; Toshirou,Nishida ^[3] ; Shuichi,Ohkubo ^[4] ; Hiromi,Kazuno ^[4] ; Yurina,Saito ^[1] ; Satoshi,Serada ^[5] ; Minoru,Fujimoto ^[6] ; Yukinori,Kurokawa ^[1] ; Takuro,Saito ^[1] ; Kazuyoshi,Yamamoto ^[1] ; Kotaro,Yamashita ^[1] ; Koji,Tanaka ^[1] ; Tomoki,Makino ^[1] ; Kiyokazu,Nakajima ^[1] ; Seiichi,Hirota ^[7] ; Tetsuji,Naka ^[5] ; Hidetoshi,Eguchi ^[6] ; Yuichiro,Doki ^[1]

作者单位： Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita-City, Osaka, Japan. ^[1] National Cancer Center Research Institute, Laboratory of Intracellular Traffic and Oncology, Tsukiji, Japan. ^[2] Department of Surgery, Japan Community Health Care Organization Osaka Hospital, Osaka, Japan. ^[3] Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan. ^[4] Institute for Biomedical Sciences Molecular Pathophysiology, Iwate Medical University School of Medicine, Yahaba, Japan. ^[5] Division of Allergy and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan. ^[6] Department of Surgical Pathology, Hyogo College of Medicine, Nishinomiya, Japan. ^[7]

关键词 GISTs angiogenesis imatinib-resistant pimitespib sunitinib